Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEDI7247 in Advanced Solid Tumors
NCT03811652Phase 1Completed
- Sponsor
- MedImmune
- Start
- Dec 2018
- Primary completion
- Dec 2019
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of MEDI7247 in squamous cell carcinoma of the lung (SCCL), head and neck squamous cell carcinoma (HNSCC), small cell lung cancer (SCLC) and 4 more (6 arms), sponsored by MedImmune. Primary endpoints: Occurrence of Adverse Events, Occurrence of Serious Adverse Events and 4 more. Started Dec 2018; status: completed.
02
Drugs
MEDI7247
03
Conditions
squamous cell carcinoma of the lung (SCCL)head and neck squamous cell carcinoma (HNSCC)small cell lung cancer (SCLC)pancreatic ductal adenocarcinoma (PDAC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT03811652.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03811652.